CVKD
Cadrenal Therapeutics, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$12.46M
P/E Ratio
—
EPS
$-6.64
Beta
1.55
52W High
$17.50
52W Low
$4.21
50-Day MA
$6.66
200-Day MA
$10.25
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for renal diseases and kidney-related disorders. By addressing significant unmet medical needs, Cadrenal utilizes its proprietary drug platforms to advance its promising candidates through rigorous clinical trials. With a robust commitment to scientific excellence and a patient-centric ethos, the company is poised to make a substantial impact in the renal therapeutic landscape, indicating potential for significant growth within the evolving biopharmaceutical sector.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-13.45M |
| Operating Margin | 0.00% |
| Return on Equity | -260.10% |
| Return on Assets | -116.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.17 |
| Price-to-Book | 4.47 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.21 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $2.51M |
| Float | $1.98M |
| % Insiders | 20.86% |
| % Institutions | 8.06% |
Historical Volatility
HV 10-Day
155.97%
HV 20-Day
116.20%
HV 30-Day
104.54%
HV 60-Day
106.20%
HV Rank
69.4%
Volatility is currently expanding
Analyst Ratings
Consensus ($27.67 target)
1
BuyData last updated: 4/10/2026